Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2018-12-10
Target enrollment:
Participant gender:
Summary
To determine if erlotinib given orally along with concurrent whole brain irradiation in lung
cancer patients with brain metastases improves median overall survival and enhances local
control compared to those treated with WBRT alone, without significantly increasing the risk
of side effects or lowering quality of life.